Genzyme: Why Diversification is Starting to Look Smart

As the blockbuster model comes under threat, Genzyme's highly diversified approach begins to look smart. Plenty of larger companies likely envy Genzyme's specialist expertise, tight customer relationships and long-standing embrace of external R&D. It's up to CEO Henri Termeer to prove that these strengths warrant an independent future for Genzyme.

Melanie Senior

Like most Big Biotechs, Genzyme Corp. has been associated with one major drug—its Gaucher’s disease treatment imiglucerase (Cerezyme). With sales...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo